Agentic AI in Pharma: Use Cases and a Practical Implementation Roadmap

Somewhere in a large pharmaceutical company, a clinical trial protocol that used to take a team of medical writers six months to produce came back as a first draft in days. A real submission-grade document, with correct terminology, validated citations, and regulatory formatting intact. Senior medical writers reviewed it and signed off. The system that produced it was not a chatbot.

It was a team of AI agents that planned the work, pulled from internal content platforms and external scientific databases, checked its own output against regulatory guidelines, and flagged the sections a human needed to verify.

That engagement is what “agentic AI in pharma” looks like on the ground, a next step for digital health solutions in a high-stakes industry where accuracy, compliance, and patient outcomes are critical. McKinsey estimates that 75 to 85 percent of pharma workflows contain tasks that can be automated or augmented by AI agents.

So now the pharma C-suites move from if to how to apply agentic AI in a pharmaceutical context, working cases, and a roadmap for taking it from pilot to production without running afoul of GxP, the FDA, or their own quality organization.

How is AI used in pharma today?

Pharma’s AI honeymoon is officially over. Machine learning has screened compounds and predicted toxicity for over a decade; natural language processing has mined literature and trial registries for years. Generative AI added a productivity layer on top: medical writing assistants, regulatory Q&A copilots, HCP content generation, etc.

What changed in 2024–2026 is the reasoning capability of foundation models and the maturation of agentic AI in life sciences that lets those models take actions safely. The gap is implementation. Pharma’s regulatory obligations, validated-system requirements, and fragmented data estates make “just deploy it” a non-starter. Which is why the use cases for agentic AI in the pharmaceutical industry concentrate where documentation burden, data volume, and latency costs are highest.

What is agentic AI in pharma?

That definition deserves unpacking, because the market is drowning in loose usage. In pharma, teams deal with constant change: live data, new research, regulatory updates, and patient-safety information. Agentic AI, by design, can keep pace with new inputs, adjust the workflow, and respond as conditions change.

A generative AI model drafts. An agent does the actual job. Instead of waiting for step-by-step instructions, agentic AI in pharma acts as an autonomous partner. Give a generative model a prompt, and it returns text. Give an agentic system an objective, like “identify all sites likely to under-enroll in Q3 and propose mitigation,” and it decomposes that goal into steps, queries your CTMS and EHR feeds, runs the analysis, drafts recommendations, and routes them to a human for approval.

The technical anatomy typically involves three layers: a large language model (LLM) for reasoning and language work, an orchestration layer that plans and sequences tasks, and tool integrations, like APIs into databases, laboratory systems, and document repositories that let the agent act on the world.

In life sciences, the multi-agent systems coordinate specialized agents like a project team for retrieval, drafting, verification, and compliance checking. That was the architecture behind BCG’s medical-writing engagement – several agents with divided labor and a governance layer on top.

Generative AI vs. agentic AI in the pharmaceutical industry

Both generative AI and agentic AI for pharma matter, because they combine the ability to synthesize insights from complex scientific and operational data with the autonomy to coordinate and carry out multi-step processes. Generative AI in pharma has already proven value. Roughly 25% of biopharma companies report that AI accounted for cost reductions and revenue increases of at least 5%. As a step further, agentic AI is what happens when you stop asking the model to write things and start asking it to run things.

Agentic AI use cases in the pharmaceutical industry

Pharma has no shortage of AI pilots. The more useful question is where an agent actually takes work off the critical path. Agentic AI in pharma industry matters most when it connects steps that used to depend on constant human coordination.

Drug discovery & development

Drug discovery gets the headlines, but the real progress is the ability to keep the research loop moving.

Agents can run in-silico screening campaigns, prioritize targets, predict toxicity, and iteratively design molecules, with each cycle feeding the next instead of waiting for another scientist’s prompt. As already mentioned, generative approaches alone have cut early discovery timelines by 25%. Agentic orchestration can push that further by connecting hypothesis generation, virtual screening, and literature synthesis into one continuous workflow. Recent scholarship in Drug Discovery Today catalogs case studies across literature synthesis, target identification, molecular design, and lab-in-the-loop experimental orchestration.

Some analyses also report AI-discovered drug candidates reaching Phase I success rates above historical baselines.

Clinical trials

Clinical trials are where promising science meets operational reality, and where delays compound quickly. The common thread is less glamorous than “autonomous clinical trials,” but more useful: agents take on the continuous matching, checking, monitoring, and coordination between major decisions, while clinicians and trial teams remain responsible for the decisions themselves.

• Patient recruitment: AI can match patient information against complex eligibility criteria and reduce the amount of manual screening required. In the TrialGPT study, clinicians using the system spent 42.6% less time screening patient-trial matches.
• Site selection and monitoring: agents can analyze site performance and patient demographics, then track activation and enrollment as the study runs. McKinsey describes a pharma trial-management copilot that identifies underperforming sites early and recommends corrective action.
• Clinical data management: rather than waiting for data-cleaning queues to build up, agents can identify and prioritize discrepancies as data arrives. McKinsey estimates these approaches can generate two to three times fewer queries for data managers and clinical research associates.
• Medical writing: BCG describes a pharma company where a single clinical-trial protocol could take medical writers about six months. Its multi-agent writing system connects internal content and regulatory systems with external scientific sources, while senior medical writers reported no loss of scientific rigor.

This is already moving beyond prototypes. IQVIA reported that agentic orchestration can compress end-to-end commercial planning and execution cycles from 6–18 months.

ConcertAI launched its Accelerated Clinical Trials platform in 2026, bringing AI-assisted protocol design, cohort identification, site selection, and real-time trial monitoring into one clinical-operations product.

Pharmacovigilance and drug safety

Pharmacovigilance (PV) is the use case where agents’ economics look most obvious: enormous case volumes, heavy documentation, and workflows already organized around structured taxonomies such as MedDRA and WHODrug.

Modern safety systems process millions of adverse-event reports each year, and manual case processing becomes harder to scale as FAERS (FDA Adverse Event Reporting System) volumes grow. Practical agentic AI advantage for pharma spans the safety workflow:

• Case intake and processing: agents can extract adverse-event information, validate if a case contains the required fields, check for duplicates, support coding and triage, and assemble an ICSR for review. In one production deployment, Boehringer Ingelheim reported up to 90% average data-extraction accuracy within weeks of introducing ArisGlobal’s NavaX for safety case intake.
• Signal detection: agentic systems can look for patterns across structured safety databases, EHRs, literature, and other unstructured data, rather than reviewing each source in isolation. IQVIA describes agents that contextualize findings across sources and recommend next steps for safety teams.
• Case and signal documentation: a 2026 Journal of Medical Artificial Intelligence review lays out specialized agents for ICSR generation, signal validation, benefit-risk analysis, and aggregate reporting, essentially breaking a long PV workflow into smaller jobs that can be coordinated by an agentic system.
• Continuous surveillance: the same architecture can take in new safety information as it arrives and reprioritize work when new evidence, regulatory alerts, or reviewer feedback changes the picture. The point is not simply faster classification; it is keeping the safety workflow current as the evidence changes.

This is also where the limits of autonomy become very clear. IQVIA’s proposed signal-management approach keeps a human in the loop, requires the AI’s reasoning to be traceable, and has safety professionals review its output. The JMAI review reaches much the same conclusion for safety-critical decisions.

The working model refocuses from “AI decides” to “AI keeps the case moving.” Agents can gather, check, compare, prioritize, and draft; qualified safety professionals remain responsible for the judgment that follows.

Manufacturing and supply chain

In manufacturing, agentic AI earns its keep before a deviation becomes a batch problem. The job shifts to watching what is happening, connecting the signals, and getting the right response moving early.

Agents can analyze equipment telemetry, batch records, deviation histories, and other operational data to spot anomalies, support root-cause analysis, and flag maintenance or process issues before they escalate. Across the supply chain, the same model applies to temperature-sensitive products: monitoring cold-chain conditions, detecting emerging excursions, and triggering actions, like escalation or shipment rerouting.

But this is also where Responsible AI becomes an operating requirement. In April 2026, FDA issued a warning letter after a drug manufacturer relied on AI agents to create cGMP specifications, procedures, and production records without adequate human review. FDA made the boundary clear: AI can assist with regulated work, but accountability stays with the manufacturer and its Quality Unit.

That sets a real pattern for agentic manufacturing: let agents monitor, connect, recommend, and act within validated boundaries; keep people accountable for quality-critical decisions.

Regulatory and compliance

Regulatory work has a stubborn problem: the documentation keeps moving. Evidence changes, submissions develop, and one update can ripple across an entire dossier.

Agentic AI is starting to take on the work around those decisions. McKinsey describes agents drafting submission documents, mapping source data to report sections, checking consistency across related files, and flagging content that may raise regulatory questions. The judgment stays with the regulatory professional; the agent handles more of the searching, checking, and first-pass work.

The FDA is applying the same basic human-plus-agent model inside the agency. In December 2025, they deployed agentic AI capabilities for all employees to help with multi-step tasks including meeting management, pre-market reviews, review validation, post-market surveillance, inspections, and compliance. The models run in a high-security GovCloud environment and, according to the agency, do not train on input data or information submitted by regulated industry. FDA also explicitly includes human oversight in the system’s built-in guidelines.

Commercial and pharma sales

Commercial teams face their own version of the same problem: HCP signals arrive across channels, CRM data ages quickly, and reps still have only minutes to work out what matters before the next conversation.

Agentic AI in pharma is set to compress that gap between signal and action. Agents can pull together HCP engagement data, surface next-best actions, prepare reps with relevant context before a call, and support more dynamic targeting and segmentation. IQVIA’s Field Force Agent, for example, combines CRM integration, real-time HCP profiles, and AI-driven recommendations to support compliant field engagement. Salesforce’s Agentforce for Life Sciences follows a similar pattern with Next Best Customer, Next Best Message, and Next Best Action capabilities.

The practical application comes to shrinking the distance between what the organization knows and what the rep can use. The agent handles more of the searching, synthesis, and recommendation; the field team still owns the interaction.

A practical roadmap of how to implement agentic AI in pharma

As our own Intellias experience shows, start with the boring process. The best first agent is rarely designing a molecule or changing a manufacturing parameter. It is more likely screening cases, assembling a protocol draft, checking documents, reconciling data, or preparing material for review.

These steps are easier to measure, easier to constrain, and usually end with a qualified human making the consequential decision.

1. Pick a workflow you can judge

Start where people repeatedly move information between systems, documents, and decisions.

A useful first case has:

• a measurable baseline
• accessible source data
• an output that can be objectively reviewed
• a clear owner when something goes wrong

Protocol drafting, literature monitoring, pharmacovigilance triage, and parts of clinical-site screening fit that pattern better than open-ended scientific or quality-critical autonomy.

Keep the scope narrow: one process, one user group, one definition of success.

2. Give the agent a controlled view of the data

An agent does not need the whole enterprise data estate. It needs trusted access to the sources required for its job.

Define which systems it can reach, which source wins when records conflict, who can access sensitive data, and what information can leave the environment. Build a known-good evaluation set before the pilot starts.

Without that baseline, a convincing answer can easily be mistaken for a correct one.

3. Set the autonomy boundary before testing

“Human in the loop” is too vague to be useful. Decide upfront:

• what the agent may do independently
• what it may prepare but a person must approve
• what it cannot do

A regulatory-writing agent might retrieve evidence and prepare a draft but never submit it. A safety agent might prioritize cases while leaving causality and escalation decisions to qualified professionals.

Log what the agent used, produced, and recommended along with what the reviewer accepted, changed, or rejected.

4. Validate the use case, not AI in the abstract

The useful question is not “Is the model validated?” It is “Validated for what job, under what conditions, and at what level of risk?”

FDA’s current framework follows that logic: define the context of use, assess the risk, and establish credibility proportionate to it. For GxP workflows, involve Quality early and define requirements, acceptance thresholds, failure handling, records, and change control around the specific regulated process the agent touches.

5. Integrate only as far as the job requires

An agent becomes operationally useful when it can work with the systems behind the process: CTMS, LIMS, RIM, safety platforms, CRM, ERP, or document repositories.

But access should be deliberately narrow. Use governed interfaces, least-privilege credentials, separate read and write permissions, and logged tool activity.

Reading a record and recommending an action is one level of risk. Changing that record is a totally different one.

6. Scale complexity only when it earns its place

Multi-agent systems make sense when a workflow genuinely contains distinct jobs, like retrieval, drafting, verification, and coordination.

BCG’s medical-writing example follows that pattern. But adding more agents does not automatically make a system more mature; it also creates more interactions and failure paths to govern.

As deployment expands, monitor output quality, human overrides, source use, model and tool changes, and whether the original business case still holds.

The hard part is rarely getting an agent to do something. It is deciding exactly what it is allowed to do when nobody is supervising every step.

Before production, be able to answer:

• What exactly is the agent responsible for?
• How will performance be measured?
• Who owns the business outcome and the risk?
• Which actions require approval?
• Can we reconstruct what the agent saw and did?
• What happens when it fails?
• What changes trigger reassessment?
• Can the capability be disabled without breaking the underlying process?

How agentic AI can work on Google Cloud at enterprise scale

At enterprise level, a Google Cloud-based design can keep agents close to governed data and existing systems while giving teams explicit control over access, actions, and review. Two practical reference patterns are:

Clinical trial operations agent. A team could use Vertex AI Agent Builder to orchestrate an agent that works with approved trial data in BigQuery and healthcare data exposed through Cloud Healthcare API. The agent could identify enrollment or data-quality exceptions, prepare a mitigation brief, and route it to the study team for approval rather than changing trial records on its own.

Regulatory and safety document agent. A second pattern could combine Vertex AI with Document AI and approved content stored in Google Cloud. The agent could extract information from source documents, retrieve relevant evidence and SOPs, check a draft for missing or inconsistent content, and send the result to a qualified reviewer. Identity and Access Management and Cloud Audit Logs can support controlled access and traceability around the workflow.

The enterprise principle is consistent across both examples: the agent can search, compare, draft, and recommend within defined permissions, while accountable pharma professionals approve consequential actions.

Challenges, risk, and Responsible AI in pharma

Responsible AI in pharma becomes useful only when it changes how the system is built and operated. It means putting the right human at the right decision point, with enough evidence and authority to act.

The starting point is context of use. An agent summarizing internal literature carries a different risk from one influencing a safety decision, generating regulatory evidence, or touching a manufacturing record. Controls should match that difference. Five areas matter most:

• Privacy and data governance. Define what data the agent can access, where processing happens, what providers retain, and whether sensitive information can be used for training
• Validation. Test the specific task against representative cases, known failure modes, and explicit acceptance thresholds.
• Human accountability. Name the reviewer or approver, define what they see, and keep consequential decisions with qualified professionals.
• Traceability. Preserve enough evidence to reconstruct the sources, model or system version, tool actions, and approvals behind an important output.
• Lifecycle control. Reassess material changes to models, prompts, retrieval sources, permissions, or orchestration logic rather than treating validation as a one-time event.

The people side matters just as much. Agentic AI in the pharmaceutical industry does not simply remove tasks; it changes where professional judgment enters the workflow. Medical writers review earlier. Safety professionals spend less time assembling cases and more time on exceptions. Regulatory specialists supervise work that demanded hours of manual preparation before.

That requires clear roles for who uses the agent, who reviews it, who approves the result, and who remains accountable.

On a final note: Why the agentic AI for pharma

Strip away the terminology, and the case for agentic AI in pharma industry comes down to four things executives already measure. It removes the waiting, searching, checking, and handoffs that make complex pharma workflows slow in the first place.

That changes the economics in a few practical ways:

• Less dead time between decisions. An agent can carry work from one step to the next, gathering evidence, preparing a draft, checking it, routing it, and surfacing the exception instead of leaving each handoff in another line.
• Experts spend more time being experts. Scientists, medical writers, safety professionals, and regulatory teams can spend less time gathering information and chasing status, and more time reviewing evidence and making decisions.
• Consistency becomes part of the workflow. Approved terminology, templates, source material, and required checks can be applied every time work moves through the process, with human review where the risk demands it.
• Fragmented systems become easier to work across. Agents can coordinate information and actions across the tools a process already depends on rather than forcing people to manually stitch the context together.
• The value compounds across the process. Saving time on one draft is useful. Keeping discovery, trial operations, safety, regulatory work, and commercial execution moving with fewer manual stops is where agentic AI becomes an operating-model change.

There is an important dividing line here. Pharma does not need autonomous agents making consequential decisions on their own. It needs Responsible AI that can do more of the work between those decisions, with traceability, clear boundaries, and people still accountable for the outcome.